

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (pages i - xiii).

In the Claims

Please amend Claims 9, 34, 45 and 48. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - xiii).

02 ⁵⁴⁶

A4

9. (Amended) A D-peptide selected from the group consisting of:

- (a) CDLKAKEFWLC (SEQ ID NO: 3);
- (b) CEARHREAWLC (SEQ ID NO: 4);
- (c) CELLGWEAWLC (SEQ ID NO: 5);
- (d) CLLRAPEWGWLC (SEQ ID NO: 6);
- (e) CSRSQPEWEWLC (SEQ ID NO: 7);
- (f) CGLGQEEFWLC (SEQ ID NO: 8);
- (g) CMRGEWEWSWLC (SEQ ID NO: 9);
- (h) CPPLNKEAWLC (SEQ ID NO: 10);
- (i) CVLKAKEFWLC (SEQ ID NO: 11);
- (j) KKGACGLGQEEFWLC (SEQ ID NO: 15);
- (k) KKGACCELLGWEAWLC (SEQ ID NO: 16);
- (l) KKKKGACCELLGWEAWLC (SEQ ID NO: 17);
- (m) KKGACMRGEWEWSWLC (SEQ ID NO: 18);
- (n) KKGACPPLNKEAWLC (SEQ ID NO: 19);
- (o) a D-peptide comprising WXWL (SEQ ID NO: 23);
- (p) a D-peptide comprising EWXWL (SEQ ID NO: 24);
- (q) a D-peptide comprising CXXXXXEWXWL (SEQ ID NO: 12);

- D1
Cot
A4
- (r) ac-GACEARHREWAWLCAA-am (SEQ ID NO: 34);
 - (r) ac-KKGACEARHREWAWLCAA-am (SEQ ID NO: 38);
 - (t) ac-KKKKGACEARHREWAWLCAA-am (SEQ ID NO: 43);
 - (u) ac-GACGLGQEEFWLCAA-am (SEQ ID NO: 44);
 - (v) ac-KKGACGLGQEEFWLCAA-am (SEQ ID NO: 64);
 - (w) ac-KKKKGACGLGQEEFWLCAA-am (SEQ ID NO: 45)
 - (x) ac-GACDLKAKEFWLCAA-am (SEQ ID NO: 35);
 - (y) ac-KKGACDLKAKEFWLCAA-am (SEQ ID NO: 39);
 - (z) ac-KKKKGACDLKAKEFWLCAA-am (SEQ ID NO: 46);
 - (a') ac-GACELLGWEAWLCC-am (SEQ ID NO: 47);
 - (b') ac-KKGACELLGWEAWLCAA-am (SEQ ID NO: 65);
 - (c') ac-KKKKGACELLGWEAWLCAA-am (SEQ ID NO: 66);
 - (d') ac-GACSRSQPEWEWLCAA-am (SEQ ID NO: 36);
 - (e') ac-KKGACSRSQPEWEWLCAA-am (SEQ ID NO: 40);
 - (f') ac-KKKKGACSRSQPEWEWLCAA-am (SEQ ID NO: 48);
 - (g') ac-GACLLRAPEWGWLCAA-am (SEQ ID NO: 37);
 - (h') ac-KKGACLLRAPEWGWLCAA-am (SEQ ID NO: 41);
 - (i') ac-KKKKGACLLRAPEWGWLCAA-am (SEQ ID NO: 49);
 - (j') ac-GACMRGEWEWSWLCAA-am (SEQ ID NO: 50);
 - (k') ac-KKGACMRGEWEWSWLCAA-am (SEQ ID NO: 67);
 - (l') ac-KKKKGACMRGEWEWSWLCAA-am (SEQ ID NO: 51);
 - (m') ac-GACPPLNKEWAWLCAA-am (SEQ ID NO: 52);
 - (n') ac-KKGACPPLNKEWAWLCAA-am (SEQ ID NO: 68);
 - (o') ac-KKKKGACPPLNKEWAWLCAA-am (SEQ ID NO: 53);
 - (p') ac-GACXXXXXEWXWLCAA-am (SEQ ID NO: 54);
 - (q') ac-KKGACXXXXXEWXWLCAA-am (SEQ ID NO: 55);
 - (r') ac-KKKKGACXXXXXEWXWLCAA-am (SEQ ID NO: 56);

AS
cont
H4

- (s') ac-XXCXXXXXXEWXWLCXX-am (SEQ ID NO: 57);
- (t') ac-KKXXCXXXXXXEWXWLCXX-am (SEQ ID NO: 58);
- (u') ac-KKKKXXCXXXXXXEWXWLCXX-am (SEQ ID NO: 59);
- (v') ac-XXCXXXXXXEWXWLCXXX-am (SEQ ID NO: 60);
- (w') ac-KKXXCXXXXXXEWXWLCXXX-am (SEQ ID NO: 61);
- (x') ac-KKKKXXCXXXXXXEWXWLCXXX-am (SEQ ID NO: 62); and
- (y') a variant of a sequence of (a) through (x'), wherein the variant binds the N-helix coiled-coil cavity of HIV gp41, wherein ac- at the C-terminus and -am at the N-terminus are optional.

34. (Amended) The method of Claim 28 wherein the D-peptide of (e) comprises an amino acid sequence selected from the group consisting of:

AS

- (a) CDLKAKEFWWLC (SEQ ID NO: 3);
- (b) CEARHREWAWLC (SEQ ID NO: 4);
- (c) CELLGWEWAWLC (SEQ ID NO: 5);
- (d) CLLRAPEWGWLC (SEQ ID NO: 6);
- (e) CSRSQPEWEWLC (SEQ ID NO: 7);
- (f) CGLGQEEFWWLC (SEQ ID NO: 8);
- (g) CMRGEWEWSWLC (SEQ ID NO: 9);
- (h) CPPLNKEWAWLC (SEQ ID NO: 10);
- (i) CVLKAKEFWWLC (SEQ ID NO: 11);
- (j) KKGACGLGQEEFWWLC (SEQ ID NO: 15);
- (k) KKGACCELLGWEWAWLC (SEQ ID NO: 16);
- (l) KKKKGACCELLGWEWAWLC (SEQ ID NO: 17);
- (m) KKGACMRGEWEWSWLC (SEQ ID NO: 18);
- (n) KKGACPPLNKEWAWLC (SEQ ID NO: 19);
- (o) a D-peptide comprising WXWL (SEQ ID NO: 23);

A5

- (p) a D-peptide comprising EWXWL (SEQ ID NO: 24);
- (q) a D-peptide comprising CXXXXXEWXWL (SEQ ID NO: 12);
- (r) ac-GACEARHREWAWLCAA-am (SEQ ID NO: 34);
- (r) ac-KKGACEARHREWAWLCAA-am (SEQ ID NO: 38);
- (t) ac-KKKKGACEARHREWAWLCAA-am (SEQ ID NO: 43);
- (u) ac-GACGLGQEEFWLCAA-am (SEQ ID NO: 44);
- (v) ac-KKGACGLGQEEFWLCAA-am (SEQ ID NO: 64);
- (w) ac-KKKKGACGLGQEEFWLCAA-am (SEQ ID NO: 45);
- (x) ac-GACDLKAKEFWLCAA-am (SEQ ID NO: 35);
- (y) ac-KKGACDLKAKEFWLCAA-am (SEQ ID NO: 39);
- (z) ac-KKKKGACDLKAKEFWLCAA-am (SEQ ID NO: 46);
- (a') ac-GACELLGWEWAWLCC-am (SEQ ID NO: 47);
- (b') ac-KKGACELLGWEWAWLCAA-am (SEQ ID NO: 65);
- (c') ac-KKKKGACELLGWEWAWLCAA-am (SEQ ID NO: 66);
- (d') ac-GACSRSQPEWEWLCAA-am (SEQ ID NO: 36);
- (e') ac-KKGACSRSQPEWEWLCAA-am (SEQ ID NO: 40);
- (f') ac-KKKKGACSRSQPEWEWLCAA-am (SEQ ID NO: 48);
- (g') ac-GACLLRAPEWGWLCAA-am (SEQ ID NO: 37);
- (h') ac-KKGACLLRAPEWGWLCAA-am (SEQ ID NO: 41);
- (i') ac-KKKKGACLLRAPEWGWLCAA-am (SEQ ID NO: 49);
- (j') ac-GACMRGEWEWSWLCAA-am (SEQ ID NO: 50);
- (k') ac-KKGACMRGEWEWSWLCAA-am (SEQ ID NO: 67);
- (l') ac-KKKKGACMRGEWEWSWLCAA-am (SEQ ID NO: 51);
- (m') ac-GACPPLNKEWAWLCAA-am (SEQ ID NO: 52);
- (n') ac-KKGACPPLNKEWAWLCAA-am (SEQ ID NO: 68);
- (o') ac-KKKKGACPPLNKEWAWLCAA-am (SEQ ID NO: 53);
- (p') ac-GACXXXXXEWXWLCAA-am (SEQ ID NO: 54);

- 175
- (q') ac-KKGACXXXXXEWXWLCAA-am (SEQ ID NO: 55);
 - (r') ac-KKKKGACXXXXXEWXWLCAA-am (SEQ ID NO: 56);
 - (s') ac-XXCXXXXXEWXWLCXX-am (SEQ ID NO: 57);
 - (t') ac-KKXXCXXXXXEWXWLCXX-am (SEQ ID NO: 58);
 - (u') ac-KKKKXXCXXXXXEWXWLCXX-am (SEQ ID NO: 59);
 - (v') ac-XXCXXXXXEWXWLCXXX-am (SEQ ID NO: 60);
 - (w') ac-KKXXCXXXXXEWXWLCXXX-am (SEQ ID NO: 61);
 - (x') ac-KKKKXXCXXXXXEWXWLCXXX-am (SEQ ID NO: 62); and
 - (y') a variant of a sequence of (a) through (x'), wherein the variant binds the N-helix coiled-coil cavity of HIV gp41, wherein ac- at the C-terminus and -am at the N-terminus are optional.
-

45. (Amended) A D-peptide which comprises an amino acid sequence selected from the group consisting of:

- 176
- (a) CDLKAKEFWWLC (SEQ ID NO: 3);
 - (b) CEARHREWAWLC (SEQ ID NO: 4);
 - (c) CELLGWEWAWLC (SEQ ID NO: 5);
 - (d) CLLRAPEWGWLC (SEQ ID NO: 6);
 - (e) CSRSQPEWEWLC (SEQ ID NO: 7);
 - (f) CGLGQEEFWWLC (SEQ ID NO: 8);
 - (g) CMRGEWEWSWLC (SEQ ID NO: 9);
 - (h) CPPLNKEWAWLC (SEQ ID NO: 10);
 - (i) CVLKAKEFWWLC (SEQ ID NO: 11);
 - (j) KKGACGLGQEEFWWLC (SEQ ID NO: 15);
 - (k) KKGACELLGWEWAWLC (SEQ ID NO: 16);
 - (l) KKKKGACELLGWEWAWLC (SEQ ID NO: 17);
 - (m) KKGACMRGEWEWSWLC (SEQ ID NO: 18);

- 176
- (n) KKGACPPLNKEWAWLC (SEQ ID NO: 19);
 - (o) a D-peptide comprising WXWL (SEQ ID NO: 23);
 - (p) a D-peptide comprising EWXWL (SEQ ID NO: 24);
 - (q) a D-peptide comprising CXXXXXEWXWL (SEQ ID NO: 12);
 - (r) ac-GACEARHREWAWLCAA-am (SEQ ID NO: 34);
 - (r) ac-KKGACEARHREWAWLCAA-am (SEQ ID NO: 38);
 - (t) ac-KKKKGACEARHREWAWLCAA-am (SEQ ID NO: 43);
 - (u) ac-GACGLGQEEFWLCAA-am (SEQ ID NO: 44);
 - (v) ac-KKGACGLGQEEFWLCAA-am (SEQ ID NO: 64);
 - (w) ac-KKKKGACGLGQEEFWLCAA-am (SEQ ID NO: 45);
 - (x) ac-GACDLKAKEFWLCAA-am (SEQ ID NO: 35);
 - (y) ac-KKGACDLKAKEFWLCAA-am (SEQ ID NO: 39);
 - (z) ac-KKKKGACDLKAKEFWLCAA-am (SEQ ID NO: 46);
 - (a') ac-GACELLGWEWAWLCC-am (SEQ ID NO: 47);
 - (b') ac-KKGACELLGWEWAWLCAA-am (SEQ ID NO: 65);
 - (c') ac-KKKKGACELLGWEWAWLCAA-am (SEQ ID NO: 66);
 - (d') ac-GACSRSQPEWEWLCAA-am (SEQ ID NO: 36);
 - (e') ac-KKGACSRSQPEWEWLCAA-am (SEQ ID NO: 40);
 - (f') ac-KKKKGACSRSQPEWEWLCAA-am (SEQ ID NO: 48);
 - (g') ac-GACLLRAPEWGWLCAA-am (SEQ ID NO: 37);
 - (h') ac-KKGACLLRAPEWGWLCAA-am (SEQ ID NO: 41);
 - (i') ac-KKKKGACLLRAPEWGWLCAA-am (SEQ ID NO: 49);
 - (j') ac-GACMRGEWEWSWLCAA-am (SEQ ID NO: 50);
 - (k') ac-KKGACMRGEWEWSWLCAA-am (SEQ ID NO: 67);
 - (l') ac-KKKKGACMRGEWEWSWLCAA-am (SEQ ID NO: 51);
 - (m') ac-GACPPLNKEWAWLCAA-am (SEQ ID NO: 52);
 - (n') ac-KKGACPPLNKEWAWLCAA-am (SEQ ID NO: 68);

- (o') ac-KKKKGACPPLNKEWAWLCAA-am (SEQ ID NO: 53);
 (p') ac-GACXXXXXEWWLCAA-am (SEQ ID NO: 54);
 (q') ac-KKGACXXXXXEWWLCAA-am (SEQ ID NO: 55);
 (r') ac-KKKKGACXXXXXEWWLCAA-am (SEQ ID NO: 56);
 (s') ac-XXCXXXXXEWWLCXX-am (SEQ ID NO: 57);
 (t') ac-KKXXCXXXXXEWWLCXX-am (SEQ ID NO: 58);
 (u') ac-KKKKXXCXXXXXEWWLCXX-am (SEQ ID NO: 59);
 (v') ac-XXCXXXXXEWWLCXXX-am (SEQ ID NO: 60);
 (w') ac-KKXXCXXXXXEWWLCXXX-am (SEQ ID NO: 61);
 (x') ac-KKKKXXCXXXXXEWWLCXXX-am (SEQ ID NO: 62); and
 (y') a variant of a sequence of (a) through (x'), wherein the variant binds the N-helix coiled-coil cavity of HIV gp41, wherein ac- at the C-terminus and -am at the N-terminus are optional.

48. (Amended) The method of Claim 47 wherein the peptide which binds the N-helix coiled-coil cavity of HIV gp41 is selected from the group consisting of:

- (a) CDLKAKEWFWLC (SEQ ID NO: 3);
 (b) CEARHREWAWLC (SEQ ID NO: 4);
 (c) CELLGWEWAWLC (SEQ ID NO: 5);
 (d) CLLRAPEWGWLC (SEQ ID NO: 6);
 (e) CSRSQPEWFWLC (SEQ ID NO: 7);
 (f) CGLGQEEWFWLC (SEQ ID NO: 8);
 (g) CMRGEWEWSWLC (SEQ ID NO: 9);
 (h) CPPLNKEWAWLC (SEQ ID NO: 10);
 (i) CVLKAKEWFWLC (SEQ ID NO: 11);
 (j) KKGACGLGQEEWFWLC (SEQ ID NO: 15);
 (k) KKGACCELLGWEWAWLC (SEQ ID NO: 16);


197

- (l) KKKKGACELLGWEWAWLC (SEQ ID NO: 17);
- (m) KKGACMRGEWEWSWLC (SEQ ID NO: 18);
- (n) KKGACPPLNKEWAWLC (SEQ ID NO: 19);
- (o) a D-peptide comprising WXWL (SEQ ID NO: 23);
- (p) a D-peptide comprising EWXWL (SEQ ID NO: 24);
- (q) a D-peptide comprising CXXXXXEWXWL (SEQ ID NO: 12)
- (r) ac-GACEARHREWAWLCAA-am (SEQ ID NO: 34);
- (r) ac-KKGACEARHREWAWLCAA-am (SEQ ID NO: 38);
- (t) ac-KKKKGACEARHREWAWLCAA-am (SEQ ID NO: 43);
- (u) ac-GACGLGQEEWFWLCAA-am (SEQ ID NO: 44);
- (v) ac-KKGACGLGQEEWFWLCAA-am (SEQ ID NO: 64);
- (w) ac-KKKKGACGLGQEEWFWLCAA-am (SEQ ID NO: 45);
- (x) ac-GACDLKAKEWFWLCAA-am (SEQ ID NO: 35);
- (y) ac-KKGACDLKAKEWFWLCAA-am (SEQ ID NO: 39);
- (z) ac-KKKKGACDLKAKEWFWLCAA-am (SEQ ID NO: 46);
- (a') ac-GACELLGWEWAWLCC-am (SEQ ID NO: 47);
- (b') ac-KKGACELLGWEWAWLCAA-am (SEQ ID NO: 65);
- (c') ac-KKKKGACELLGWEWAWLCAA-am (SEQ ID NO: 66);
- (d') ac-GACSRSQPEWEWLCAA-am (SEQ ID NO: 36);
- (e') ac-KKGACSRSQPEWEWLCAA-am (SEQ ID NO: 40);
- (f') ac-KKKKGACSRSQPEWEWLCAA-am (SEQ ID NO: 48);
- (g') ac-GACLLRAPEWGWLCAA-am (SEQ ID NO: 37);
- (h') ac-KKGACLLRAPEWGWLCAA-am (SEQ ID NO: 41);
- (i') ac-KKKKGACLLRAPEWGWLCAA-am (SEQ ID NO: 49);
- (j') ac-GACMRGEWEWSWLCAA-am (SEQ ID NO: 50);
- (k') ac-KKGACMRGEWEWSWLCAA-am (SEQ ID NO: 67);
- (l') ac-KKKKGACMRGEWEWSWLCAA-am (SEQ ID NO: 51);

- 17
- (m') ac-GACPPLNKEWAWLCAA-am (SEQ ID NO: 52);
 - (n') ac-KKGACPPLNKEWAWLCAA-am (SEQ ID NO: 68);
 - (o') ac-KKKKGACPPLNKEWAWLCAA-am (SEQ ID NO: 53);
 - (p') ac-GACXXXXXEWXWLCAA-am (SEQ ID NO: 54);
 - (q') ac-KKGACXXXXXEWXWLCAA-am (SEQ ID NO: 55);
 - (r') ac-KKKKGACXXXXXEWXWLCAA-am (SEQ ID NO: 56);
 - (s') ac-XXCXXXXXEWXWLCXX-am (SEQ ID NO: 57);
 - (t') ac-KKXXCXXXXXEWXWLCXX-am (SEQ ID NO: 58);
 - (u') ac-KKKKXXCXXXXXEWXWLCXX-am (SEQ ID NO: 59);
 - (v') ac-XXCXXXXXEWXWLCXXX-am (SEQ ID NO: 60);
 - (w') ac-KKXXCXXXXXEWXWLCXXX-am (SEQ ID NO: 61);
 - (x') ac-KKKKXXCXXXXXEWXWLCXXX-am (SEQ ID NO: 62); and
 - (y') a variant of a sequence of (a) through (x'), wherein the variant binds the N-helix coiled-coil cavity of HIV gp41, wherein ac- at the C-terminus and -am at the N-terminus are optional.
-

Please insert the attached "Sequence Listing" (sheets 1/20 through 20/20), and comprising SEQ ID NOS: 1-68, into the above-referenced application.

Respectfully submitted,
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 
Linda M. Chinn
Registration No. 31,240
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799
Date: August 7, 2001